IY-828026

IY-828026 is an investigational small molecule potassium-competitive acid blocker (P-CAB) developed by Il-Yang Pharm. Co., Ltd. for the treatment of gastroesophageal reflux disease (GERD). It functions by reversibly inhibiting the gastric H+/K+-ATPase enzyme, also known as the proton pump, by competing with potassium ions. Unlike traditional proton pump inhibitors (PPIs), which require acid activation and bind covalently to the pump, P-CABs like IY-828026 provide rapid and acid-independent inhibition of gastric acid secretion. This mechanism potentially offers clinical advantages such as a faster onset of action and more consistent control of gastric pH. IY-828026 is currently in early-stage clinical development, with Phase 1 trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult volunteers.